CytomX Initial CX-904 Phase 1a Clinical Data Update on May 8

- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -

- Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th-

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.

https://www.globenewswire.com/news-release/2024/05/01/2873162/37704/en/CytomX-Therapeutics-to-Report-First-Quarter-2024-Results-and-Provide-an-Initial-CX-904-Phase-1a-Clinical-Data-Update-on-May-8-2024.html